148 related articles for article (PubMed ID: 36058380)
1. Demystifying the CXCR4 conundrum in cancer biology: Beyond the surface signaling paradigm.
Nengroo MA; Khan MA; Verma A; Datta D
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188790. PubMed ID: 36058380
[TBL] [Abstract][Full Text] [Related]
2. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
3. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells.
Boudot A; Kerdivel G; Habauzit D; Eeckhoute J; Le Dily F; Flouriot G; Samson M; Pakdel F
PLoS One; 2011; 6(6):e20898. PubMed ID: 21695171
[TBL] [Abstract][Full Text] [Related]
4. A role for the CXCR4-CXCL12 axis in the little skate, Leucoraja erinacea.
Hersh TA; Dimond AL; Ruth BA; Lupica NV; Bruce JC; Kelley JM; King BL; Lutton BV
Am J Physiol Regul Integr Comp Physiol; 2018 Aug; 315(2):R218-R229. PubMed ID: 29641231
[TBL] [Abstract][Full Text] [Related]
5. The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies.
Mehrpouri M
Eur J Pharmacol; 2022 Apr; 920():174831. PubMed ID: 35183534
[TBL] [Abstract][Full Text] [Related]
6. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
7. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.
Singh AK; Arya RK; Trivedi AK; Sanyal S; Baral R; Dormond O; Briscoe DM; Datta D
Cytokine Growth Factor Rev; 2013 Feb; 24(1):41-9. PubMed ID: 22989616
[TBL] [Abstract][Full Text] [Related]
8. CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR.
Circelli L; Sciammarella C; Guadagno E; Tafuto S; del Basso de Caro M; Botti G; Pezzullo L; Aria M; Ramundo V; Tatangelo F; Losito NS; Ieranò C; D'Alterio C; Izzo F; Ciliberto G; Colao A; Faggiano A; Scala S
Oncotarget; 2016 Apr; 7(14):18865-75. PubMed ID: 26934559
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
Qiao N; Wang L; Wang T; Li H
Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
[TBL] [Abstract][Full Text] [Related]
11. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
Luker KE; Lewin SA; Mihalko LA; Schmidt BT; Winkler JS; Coggins NL; Thomas DG; Luker GD
Oncogene; 2012 Nov; 31(45):4750-8. PubMed ID: 22266857
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis ininvasive breast carcinoma: A potent biomarker predicting lymph node metastasis.
Dayer R; Babashah S; Jamshidi S; Sadeghizadeh M
J Cancer Res Ther; 2018; 14(2):345-350. PubMed ID: 29516917
[TBL] [Abstract][Full Text] [Related]
13. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
14. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
15. The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration.
Bi J; Li P; Li C; He J; Wang Y; Zhang H; Fan X; Jia R; Ge S
Tumour Biol; 2016 Mar; 37(3):4175-82. PubMed ID: 26490988
[TBL] [Abstract][Full Text] [Related]
16. Effects of the chemokine CXCL12 and combined internalization of its receptors CXCR4 and CXCR7 in human MCF-7 breast cancer cells.
Hattermann K; Holzenburg E; Hans F; Lucius R; Held-Feindt J; Mentlein R
Cell Tissue Res; 2014 Jul; 357(1):253-66. PubMed ID: 24770893
[TBL] [Abstract][Full Text] [Related]
17. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
18. Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.
Rhodes LV; Bratton MR; Zhu Y; Tilghman SL; Muir SE; Salvo VA; Tate CR; Elliott S; Nephew KP; Collins-Burow BM; Burow ME
Exp Cell Res; 2011 Nov; 317(18):2573-81. PubMed ID: 21906588
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer.
Wu W; Qian L; Chen X; Ding B
Int J Clin Exp Pathol; 2015; 8(10):13217-24. PubMed ID: 26722521
[TBL] [Abstract][Full Text] [Related]
20. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
Gravel S; Malouf C; Boulais PE; Berchiche YA; Oishi S; Fujii N; Leduc R; Sinnett D; Heveker N
J Biol Chem; 2010 Dec; 285(49):37939-43. PubMed ID: 20956518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
